31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC

Walleye Capital LLC acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 31,780 shares of the company's stock, valued at approximately $809,000. Walleye Capital LLC owned 0.06% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in BCAX. The Manufacturers Life Insurance Company bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $582,000. First Turn Management LLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at about $14,324,000. Finally, FMR LLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at about $57,913,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Bicara Therapeutics in a research report on Friday. They set a "buy" rating and a $42.00 target price on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 target price on the stock. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price on the stock. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a "buy" rating on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $43.00.

Insider Buying and Selling

In related news, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares of the company's stock, valued at $16,156,566. This represents a 8.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the acquisition, the director now directly owns 4,303,418 shares of the company's stock, valued at approximately $77,461,524. This trade represents a 74.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Trading Up 8.0 %

Shares of NASDAQ BCAX traded up $1.56 during trading on Friday, reaching $21.10. The company had a trading volume of 307,299 shares, compared to its average volume of 293,732. Bicara Therapeutics Inc. has a 52 week low of $17.41 and a 52 week high of $28.09. The business's 50 day moving average is $21.73.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.89 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.